Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in pediatric moderate-to-severe plaque psoriasis
NCT03073200Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ixekizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started Mar 2017; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03073200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03073200.